Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
Portfolio Pulse from
Lantheus Holdings commends CMS for enhancing payment for specialized diagnostic radiopharmaceuticals and reaffirms PYLARIFY's blockbuster status for 2025.
November 11, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lantheus Holdings commends CMS for updated payment rates, supporting PYLARIFY's growth. The company reaffirms its 2025 outlook for PYLARIFY as a blockbuster, expecting it to remain the top PSMA PET imaging agent in the U.S.
The CMS's updated payment rates are likely to enhance the financial performance of Lantheus by ensuring broad access to its diagnostic radiopharmaceuticals, particularly PYLARIFY. This regulatory support aligns with Lantheus's reaffirmed outlook for PYLARIFY as a blockbuster, indicating strong future revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100